drugset
drugset / Trial / NCT00496275

Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

NCT00496275 ↗

Phase 1 Completed 17 enrolled Genzyme, a Sanofi Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To test the safety and tolerability of ZD6474 in combination withVinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.

Timeline

Start
2006-08
Primary completion
—
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — —
Subject Vandetanib Small molecule — —
Subject Vinorelbine Small molecule — —
Background Cisplatin Other / unclassified — —

Indications

non-small cell lung carcinoma